Export

ATC codes: H02AB04
EMLc
Indication
Lymphoid leukaemia, NOS ICD11 code: 2C03.3
INN
Methylprednisolone
Medicine type
Chemical agent
List type
Complementary
Formulations
Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc) ; 40 mg per mL in 5 mL multi-dose vial (as sodium succinate) (EMLc) ; 80 mg per mL in 1 mL single-dose vial (as sodium succinate) (EMLc)
EML status history
First added in 2011 (TRS 965)
Changed in 2015 (TRS 994)
Sex
All
Age
Children (1 month - 12 years)
Therapeutic equivalence
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for methylprednisolone injection on the complementary list of the EMLc for use in treatment protocols for acute lymphoblastic leukaemia was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for acute lymphoblastic leukaemia is attached.